Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  ImmunoGen, Inc.    IMGN

Delayed Quote. Delayed  - 07/26 10:00:00 pm
2.78 USD   -1.07%
07/21 IMMUNOGEN, INC. : Announces Conference Call to Discuss Its Fourth Qu..
06/15 IMMUNOGEN : Announces Pricing of $100 Million Offering of 4.50% Conv..
06/13 IMMUNOGEN : Announces Proposed $100 Million Offering of Convertible ..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

ImmunoGen, Inc. : Initiates Phase I Trial in Non-Hodgkin's Lymphoma with Its Novel IMGN529 Anticancer Compound

share with twitter share with LinkedIn share with facebook
share via e-mail
0
04/17/2012 | 12:20pm CEST

- First of Two Unique ImmunoGen Product Candidates Expected to Enter Clinic in 2012 -

ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops anticancer therapeutics using its antibody expertise and Targeted Antibody Payload (TAP) technology, today announced the start of clinical testing with its IMGN529 product candidate. The Phase I trial initiated evaluates the safety, tolerability, pharmacokinetic profile and anticancer activity of escalating doses of IMGN529 in patients with non-Hodgkin's lymphoma (NHL) to establish the dose for future clinical trials.

Today NHL is frequently treated with the anticancer antibody, rituximab (Rituxan®), and/or with chemotherapy. The novel agent IMGN529, a TAP compound, contains a B-cell-targeting antibody that has demonstrated marked anticancer activity in preclinical testing.1 Attached to this antibody is a potent ImmunoGen cell-killing agent, DM1. The antibody serves: (1) to kill the cancer cells through multiple antibody-mediated mechanisms; and (2) to deliver the DM1 specifically to the cancer cells for additional, targeted anticancer potency.

"The Phase I trial now underway, together with our market research, is expected to provide the information needed to define a clear development path for IMGN529 in NHL," commented James O'Leary, MD, Vice President and Chief Medical Officer. "With its unique profile, we believe IMGN529 has the potential to be an important new therapy for the treatment of key B-cell malignancies."

About the Phase I Trial Initiated

This multi-center, first-in-human Phase I trial is expected to enroll approximately 55 patients with relapsed or relapsed/refractory, CD37-expressing NHL. Patients with follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, or marginal zone lymphoma - the more common types of NHL - are eligible for enrollment.

About IMGN529

ImmunoGen created IMGN529 for the treatment of B-cell malignancies that express its CD37 target. The prevalence of CD37 on malignant cells is similar to that of CD20, the target for rituximab: it is expressed widely on key NHL subtypes - including follicular lymphoma, diffuse large B-cell lymphoma, marginal zone lymphoma and mantle cell lymphoma - and also on chronic lymphocytic leukemia (CLL).1

IMGN529 contains a CD37-targeting ImmunoGen antibody that, in vitro, has been found to kill cancer cells through multiple mechanisms of action including pro-apoptotic activity, complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC).1,2 The attached DM1 kills cancer cells through a different mechanism - disruption of a key step that occurs during cell division.

About Non-Hodgkin's lymphoma

NHL comprises a diverse group of cancers that all derive from defects in cellular production of lymphocytes, a type of white blood cell. As the name suggests, NHL includes all lymphomas except Hodgkin's lymphoma. Approximately 85% of cases of NHL are B-cell lymphomas. It is estimated that, in the US, approximately 56,000 people are diagnosed with B-cell NHL each year and 16,000 die from the disease.3

About ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics using the Company's expertise in tumor biology, monoclonal antibodies, potent cancer-cell killing agents and engineered linkers. The Company's TAP technology uses monoclonal antibodies to deliver one of ImmunoGen's proprietary cancer-cell killing agents specifically to tumor cells. There are now numerous TAP compounds in clinical development with a wealth of clinical data reported. ImmunoGen's collaborative partners include Amgen, Bayer HealthCare, Biotest, Lilly, Novartis, Roche, and Sanofi. The most advanced compound using ImmunoGen's TAP technology, trastuzumab emtansine (T-DM1), is in Phase III testing through the Company's collaboration with Genentech, a member of the Roche Group. More information about ImmunoGen can be found at www.immunogen.com.

1Mayo M. et al., AACR 2011, abstract #4581.
2Deckert J. et al., AACR 2011, abstract #4565.
3American Cancer Society, What is non-Hodgkin's Lymphoma.

Rituxan® is a registered trademark of Biogen Idec Inc.

This press release includes forward-looking statements. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. It should be noted that there are risks and uncertainties related to the development of novel anticancer products, including IMGN529, including risks related to preclinical and clinical studies, their timings and results. A review of these risks can be found in ImmunoGen's Annual Report on Form 10-K for the fiscal year ended June 30, 2011 and other reports filed with the Securities and Exchange Commission.

For Investors:
ImmunoGen, Inc.
Carol Hausner, 781-895-0600
Executive Director, Investor Relations and Corporate Communications
info@immunogen.com
or
For Media:
The Yates Network
Kathryn Morris, 845-635-9828


© Business Wire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on IMMUNOGEN, INC.
07/21 IMMUNOGEN, INC. : Announces Conference Call to Discuss Its Fourth Quarter and Fi..
06/30 IMMUNOGEN : Study Results from ImmunoGen, Inc. in the Area of Immunoglobulins Re..
06/20 IMMUNOGEN INC : Entry into a Material Definitive Agreement, Creation of a Direct..
06/16 IMMUNOGEN : Findings from ImmunoGen, Inc. Update Understanding of Enterobacteria..
06/15 IMMUNOGEN : Announces Pricing of $100 Million Offering of 4.50% Convertible Seni..
06/13 IMMUNOGEN INC : Other Events, Financial Statements and Exhibits (form 8-K)
06/13 IMMUNOGEN : Announces Proposed $100 Million Offering of Convertible Senior Notes..
05/18 IMMUNOGEN : Reports Efficacy and Safety Data from a 46-Patient Cohort of Mirvetu..
05/12 IMMUNOGEN : Announces Initiation of Clinical Testing of First-in-Class IMGN779 f..
05/12 IMMUNOGEN : Appoints Mark J. Enyedy as President and Chief Executive Officer
More news
Sector news : Biotechnology & Medical Research - NEC
01:22p GSK chases next biotech asthma drug with 175 million pounds J&J deal
07/26 GILEAD SCIENCES : cuts 2016 sales forecast, cites hepatitis C drugs
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 2nd Update
07/25DJCELGENE : Drug Misses Secondary Endpoint in One of Its Lymphoma Trials
07/25DJGILEAD SCIENCES : Sales of Hepatitis C Drugs Fall 19% -- 3rd Update
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
07/07 ImmunoGen Oversold Despite Strong Pipeline
06/14 Midday Gainers / Losers
06/14 HEALTHCARE - TOP 5 GAINERS / LOSERS : 00 am
06/13 ImmunoGen initiates $100M convertible debt offering
05/03 SEATTLE GENETICS : Now Is A Good Time To Buy
Advertisement
Financials ($)
Sales 2016 69,2 M
EBIT 2016 -113 M
Net income 2016 -131 M
Debt 2016 19,2 M
Yield 2016 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales 2016 3,77x
EV / Sales 2017 5,73x
Capitalization 242 M
More Financials
Chart IMMUNOGEN, INC.
Duration : Period :
ImmunoGen, Inc. Technical Analysis Chart | IMGN | US45253H1014 | 4-Traders
Full-screen chart
Technical analysis trends IMMUNOGEN, INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 9
Average target price 8,50 $
Spread / Average Target 206%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Mark J. Enyedy President, Chief Executive Officer & Director
Stephen C. McCluski Chairman
David B. Johnston Chief Financial Officer & Executive Vice President
Sandra E. Poole Executive Vice President-Technical Operations
Richard J. Gregory Chief Scientific Officer & Executive VP
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
IMMUNOGEN, INC.-79.51%242
INCYTE CORPORATION-19.82%16 315
CELLTRION, INC.--.--%10 696
LONZA GROUP AG11.40%9 743
QUINTILES TRANSNATIONA..9.89%9 029
ALKERMES PLC-35.74%7 711
More Results